Arsanis (ASNS) Reaches New 1-Year Low After Earnings Miss
Arsanis Inc (NASDAQ:ASNS)’s share price hit a new 52-week low during trading on Monday after the company announced weaker than expected quarterly earnings. The company traded as low as $1.22 and last traded at $1.27, with a volume of 5150 shares changing hands. The stock had previously closed at $1.37.
The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02).
A number of analysts have issued reports on the stock. ValuEngine upgraded shares of Arsanis from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research cut shares of Arsanis from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. Finally, Piper Jaffray Companies reduced their target price on shares of Arsanis to $2.50 and set a “neutral” rating for the company in a research note on Monday, August 13th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $14.88.
The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.20. The company has a market cap of $19.61 million and a PE ratio of -0.08.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/11/14/arsanis-asns-reaches-new-1-year-low-after-earnings-miss.html.
Arsanis Company Profile (NASDAQ:ASNS)
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Read More: Ex-Dividend
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.